Department of Surgery, Massachusetts General Hospital, Boston, MA, USA.
Vascular. 2024 Dec;32(6):1226-1231. doi: 10.1177/17085381231193506. Epub 2023 Aug 6.
The optimal anti-thrombotic management of patients after lower extremity bypass has yet to be fully elucidated, in part due to significant heterogeneity in patient presentation and practice patterns. The Wound, Ischemia, and foot Infection (WIfI) score is a validated scoring system to assist in the management of patients with chronic limb threatening ischemia (CLTI). We hypothesized that performing a restriction analysis based on WIFI scores would assist in the postoperative anti-thrombotic management of patients undergoing infrainguinal bypass.
A retrospective cohort of infrainguinal bypass procedures completed at a single hospital system between January 2018 and January 2021 was selected, and preoperative WIfI scores were extracted for each patient. Patients with either Wound scores of 2 and 3, or Ischemia Scores of 0 and 1, or Foot Infection Scores of 3 were excluded. Based on the type of anti-thrombotic regimen on discharge, demographics, comorbidities, type of bypass, 30-day rates of graft occlusion, major amputation, mortality, and major adverse limb events (MALE) were analyzed. Statistical analysis included t-tests, chi square tests, and time-to-event survival analysis.
230 procedures were included in the study. 69 (30.0%) patients were discharged on single antiplatelet therapy (SAPT), compared to 161 (70.0%) who were discharged on either dual antiplatelet therapy or anticoagulation (DAPT/AC). There was a higher prevalence of bypasses using prosthetic conduit in the DAPT/AC group (45.9 vs 31.8%, = .047); no other demographic or procedural variable analyzed had any significant differences. At 30-days postoperatively, there was no significant difference in postoperative reintervention rates, however, the DAPT/AC group had significantly lower rates of mortality (1.2 vs 7.2%, = .01), major amputation (1.2% vs 5.8%, = .04), and MALE (3.7 vs 13.0%, < .01). There were no significant differences in bleeding complications. Survival analysis demonstrated that MALE-free survival was higher in the DAPT/AC group compared to the SAPT group ( < .01). On Cox regression analysis, DAPT/AC was associated with significantly decreased rates of MALE + mortality (Hazard Ratio (HR) 0.20 [0.06 - 0.66]).
Lower extremity bypasses patients with low Wound and low foot Infection scores who are discharged on DAPT/AC postoperatively have a significantly higher 30-day MALE-free survival rate compared to patients discharged on SAPT; consideration could be made to preferentially discharge such post-bypass patients on DAPT/AC.
下肢旁路术后最佳抗栓管理尚未完全阐明,部分原因是患者表现和实践模式存在显著异质性。伤口、缺血和足部感染(WIfI)评分是一种用于协助管理慢性肢体威胁性缺血(CLTI)患者的验证评分系统。我们假设基于 WIFI 评分进行限制分析将有助于指导接受下肢旁路手术患者的术后抗栓治疗。
选择了 2018 年 1 月至 2021 年 1 月期间在单一医院系统完成的下肢旁路手术的回顾性队列,提取了每位患者的术前 WIfI 评分。排除伤口评分 2 和 3 或缺血评分 0 和 1 或足部感染评分 3 的患者。根据出院时的抗栓方案类型、人口统计学、合并症、旁路类型、30 天内移植物闭塞、大截肢、死亡率和主要肢体不良事件(MALE)进行分析。统计分析包括 t 检验、卡方检验和时间至事件生存分析。
研究共纳入 230 例手术。69 例(30.0%)患者出院时接受单一抗血小板治疗(SAPT),而 161 例(70.0%)患者出院时接受双联抗血小板治疗或抗凝治疗(DAPT/AC)。DAPT/AC 组中使用人工血管旁路的比例较高(45.9% vs. 31.8%, =.047);未发现其他人口统计学或手术变量有任何显著差异。术后 30 天,再干预率无显著差异,但 DAPT/AC 组死亡率(1.2% vs. 7.2%, =.01)、大截肢率(1.2% vs. 5.8%, =.04)和 MALE 发生率(3.7% vs. 13.0%, <.01)较低。两组出血并发症无显著差异。生存分析表明,DAPT/AC 组的 MALE 无事件生存率高于 SAPT 组( <.01)。Cox 回归分析显示,DAPT/AC 与 MALE +死亡率降低显著相关(风险比(HR)0.20 [0.06-0.66])。
与接受 SAPT 出院的患者相比,术后接受 DAPT/AC 出院的下肢旁路术后 Wound 和 Foot Infection 评分较低的患者 30 天 MALE 无事件生存率显著提高;考虑优先为这些旁路术后患者开出 DAPT/AC。